



Studies in Marine Macrolide Synthesis: Construction of a 24-Membered Macrocyclic Intermediate for Aplyronine A


Ian Paterson,* Michael D. Woodrow and Cameron J. Cowden

University Chemical Laboratory, Lensfield Road, Cambridge CB2 1EW, UK.

Received 21 May 1998; accepted 8 June 1998

Abstract: The C₁–C₂₇ macrolide **2**, which contains 11 stereocentres and 4 double bonds, was constructed by an efficient 3-component coupling followed by a macrolactonisation/isomerisation sequence. Key steps were the alkylation of the dianion of phosphonate **5** with iodide **7** and a Ba(OH)₂-mediated HWE reaction with **6** to install the trisubstituted double bond. © 1998 Elsevier Science Ltd. All rights reserved.


Aplyronine A (**1**) is an unusual 24-membered marine macrolide, which displays potent antitumour activity against a range of cancers including P388 leukaemia, Lewis lung carcinoma and B16 melanoma.¹ This activity may be related to its ability to inhibit the polymerisation of globular actin to fibrous actin and to depolymerise fibrous actin to globular actin.² Due to its scarcity from the natural source and promising anti-cancer activity, a total synthesis was undertaken by the Yamada group.³ We have devised a different strategy for the stereocontrolled synthesis of the aplyronines,⁴ which is potentially shorter and features some novel aldol chemistry developed in our laboratory.



As outlined in **Scheme 1**, our strategy for the synthesis of aplyronine A (**1**) is based on the elaboration of the pivotal intermediate **2**, which corresponds to a truncated, 24-membered, macrolide having 11 of the 15 stereocentres of the full carbon chain. The subsequent introduction of the highly functionalised side-chain of the aplyronines would then be performed using a suitable HWE coupling, such as with the C₂₈–C₃₄ subunit **3** containing an *N*-methyl vinylformamide terminus.⁵ In this paper, we report the synthesis of macrocycle **2** by the controlled coupling of three subunits **4**–**6**, followed by a macrolactonisation step.

At the outset, the order of the 3-component coupling of **4**, **5** and **6** was open to change, thus allowing flexibility in our strategy. Indeed, we initially investigated the HWE addition of phosphonate **5** to aldehyde **6**, however, later difficulties were encountered with this route.^{6,7} Hence, the alkylation of the dianion of β -keto phosphonate **5** with iodide **4** was pursued instead. In this case, the C₁₄–C₁₅ (*E*)-trisubstituted double bond in **2** would be introduced by a HWE reaction, followed by an asymmetric reduction of the ketone to generate the C₁₃ stereocentre. A similar protocol proved to be effective in the synthesis of the C₁₉–C₂₁ allylic methyl ether portion of **6**.⁴


The synthesis of the C₁–C₂₇ chain of the aplyronines is shown in **Scheme 2**. Attempted alkylation of iodide **4** with the dianion of phosphonate **5** according to Gricco's conditions⁸ failed, presumably due to competing reaction at the diene ester. Therefore, the ester was first reduced to the corresponding alcohol and protected as its TBS ether **7**. This time, alkylation using the dianion of **5** in THF proceeded, albeit slowly, at -78 °C. When a small amount of HMPA (2 equiv.) was introduced, a 95% yield of the β -keto phosphonate **8** was obtained. The HWE olefination reaction between **6** and **8** proceeded in good yield (80%) using Ba(OH)₂ as a mild base.⁹ Notably, complete selectivity for **9** was realised, demonstrating that this is an effective coupling method for constructing (*E*)-trisubstituted double bonds. The C₁₃ stereocentre was then introduced with >95:5 selectivity by CBS reduction¹⁰ of the enone **9**, using the (*R*)-proline derived oxazaborolidine **10** in conjunction with BH₃•SMe₂, giving the (*S*)-alcohol **11** in 83% yield. Finally, methylation of **11** (NaH/MeI) provided the methyl ether **12**, which possesses the C₁–C₂₇ carbon chain of the aplyronines.



Scheme 2: (a) DIBAL, CH₂Cl₂, -78 °C, 2 h; (b) TBSOTf, 2,6-lutidine, CH₂Cl₂, -78 °C, 3 h; (c) NaH, THF, 0 °C, 90 min; *n*-BuLi, 0 °C, 30 min; **7**, HMPA, THF, -78 °C, 1 h; (d) Ba(OH)₂, THF, 20 °C, 30 min; **6**, THF/H₂O (40:1), 20 °C, 2.5 h; (e) (*R*)-**10**, BH₃•Me₂S, THF, 0 °C, 20 min; (f) NaH, MeI, THF, 20 °C, 4 h.

As shown in **Scheme 3**, the TBS ether at C₁ in **12** was next removed oxidatively using 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) in CH₂Cl₂/pH7 buffer (0 °C, 10 min) to give aldehyde **13** in 92% yield.¹¹ Notably, these mild, neutral conditions selectively removed the TBS ether in the presence of the di-*tert*-butylsilylene and TIPS ether, as well as the potentially labile PMP acetal. Moreover, this reaction achieved concomitant oxidation at C₁ to generate the (*E,E*)-diene aldehyde. Further oxidation of **13** using buffered sodium chlorite¹² gave acid **14** in 91% yield. Removal of the di-*tert*-butyl silylene in the presence of the primary TIPS ether was then achieved (HF•pyr) to provide seco acid **15**, in preparation for macrolactonisation.

With the seco acid **15**, there are two possible macrolactonisation products, *i.e.* **2** and **16**. At the outset, it was anticipated that some selectivity for acylation at the less sterically encumbered C₂₃ hydroxyl might be achieved.¹³ In practice, however, use of the Yonemitsu variant¹⁴ of the Yamaguchi macrolactonisation procedure¹⁵ in CHCl₃ gave exclusively the undesired, 26-membered, macrocycle **16** in 79% yield. In contrast to previous studies on macrolactonisation of related 1,3-diol systems,¹⁶ changing the solvent polarity had little effect; highlighting the uncertainty in predicting kinetic macrocyclisation selectivity in such complex cases. We decided to explore the isomerisation of **16**, which was formed in good yield, to produce the desired, 24-membered, macrocycle **2**. Treatment^{3,17} with Ti(O*i*-Pr)₄ in CH₂Cl₂ led to isomerisation of **16** with 3:1 selectivity in favour of **2** with good mass recovery (80%). The two macrolides¹⁸ were readily separated by chromatography, allowing resubmission of **16** to the isomerisation step. In this way, we were able to obtain the key intermediate **2**,⁶ having the desired 24-membered macrolide framework for the aplyronines.



Scheme 3: (a) DDQ, CH₂Cl₂, pH7 buffer, 0 °C, 10 min; (b) NaClO₂, NaH₂PO₄, H₂O, *t*-BuOH, 2-methylbut-2-ene, 20 °C, 18 h; (c) HF•pyr, pyr, THF, 20 °C; (d) 2,4,6-trichlorobenzoyl chloride, DMAP, Et₃N, CHCl₃, 20 °C, 4 h; (e) Ti(O*i*-Pr)₄, CH₂Cl₂, 20 °C, 24 h.


In conclusion, the C₁–C₂₇ macrolide **2** which contains 11 stereocentres and 4 double bonds was synthesised by an efficient 3-component coupling of subunits **5**, **6** and **7** followed by a macrolactonisation/isomerisation sequence. Studies towards the synthesis of the remaining C₂₈–C₃₄ subunit and its elaboration into aplyronine A by coupling with a suitable derivative of **2** are currently under investigation.

Acknowledgement: We thank the EPSRC (GR/K54052) and Merck Sharp & Dohme for support.

References and Notes

1. Yamada, K.; Ojika, M.; Ishigaki, T.; Yoshida, Y.; Ekimoto, H.; Arakawa, M. *J. Am. Chem. Soc.* **1993**, *115*, 11020.
2. (a) Saito, S.-y.; Watabe, S.; Ozaki, H.; Kigoshi, H.; Yamada, K.; Fusetani, N.; Karaki, H. *J. Biochem.* **1996**, *120*, 552. (b) Suenaga, K.; Kamei, N.; Okugawa, Y.; Takagi, M.; Akao, A.; Kigoshi, H.; Yamada, K. *Bioorg. Med. Chem. Lett.* **1997**, *7*, 269.
3. (a) Kigoshi, H.; Ojika, M.; Ishigaki, T.; Suenaga, K.; Mutou, T.; Sakakura, A.; Ogawa, T.; Yamada, K. *J. Am. Chem. Soc.* **1994**, *116*, 7443. (b) Kigoshi, H.; Suenaga, K.; Mutou, T.; Ishigaki, T.; Atsumi, T.; Ishiwata, H.; Sakakura, A.; Ogawa, T.; Ojika, M.; Yamada, K. *J. Org. Chem.* **1996**, *61*, 5326.

4. Paterson, I.; Cowden, C. J.; Woodrow, M. D. *Tetrahedron Lett.* **1998**, *38*, 6037.
5. Paterson, I.; Cowden, C.; Watson, C. *Synlett*, **1996**, 209.
6. All new compounds gave spectroscopic data in agreement with the assigned structures. Macrolide **2** had: $^1\text{H NMR } \delta$ (500 MHz, CDCl_3) 7.41 (2H, d, $J = 8.7$ Hz, ArH), 7.26 (2H, dd, $J = 15.0, 11.3$ Hz, H₃), 6.88 (2H, d, $J = 8.7$ Hz, ArH), 6.20 (1H, dd, $J = 14.8, 11.3$ Hz, H₄), 6.05 (1H, ddd, $J = 14.8, 9.5, 4.7$ Hz, H₅), 5.85 (1H, d, $J = 15.0$ Hz, H₂), 5.76 (1H, s, CHAr), 5.60 (1H, ddd, $J = 15.4, 10.1, 4.0$ Hz, H₂₁), 5.51 (1H, bd, $J = 10.7$ Hz, H₂₃), 5.23 (1H, dd, $J = 15.4, 8.7$ Hz, H₂₀), 5.11 (1H, t, $J = 6.8$ Hz, H₁₅), 3.95 (1H, d, $J = 6.5$ Hz, H₉), 3.90 (1H, dd, $J = 11.1, 4.0$ Hz, H₇), 3.80 (5H, m, ArOMe and 2 x H₂₇), 3.60 (1H, d, $J = 5.7$ Hz, OH), 3.55 (1H, m, H₁₉), 3.42 (1H, dd, $J = 9.0, 5.0$ Hz, H₁₃), 3.21 (3H, s, OMe), 3.17 (1H, m, H₂₅), 3.16 (3H, s, OMe), 3.11 (1H, m, H_{6A}), 2.58 (1H, m, H_{6B}), 2.52 (1H, dd, $J = 11.6, 6.0$ Hz, H_{22A}), 2.27 (1H, dm, $J = 11.6$ Hz, H_{22B}), 2.05 (1H, m, H_{16A}), 1.95 (3H, m, H₈, H₂₄ and H₂₆), 1.78 (1H, m, H_{16B}), 1.63 (1H, m, H_{12A}), 1.53 (1H, m, H₁₀), 1.48 (2H, m, H_{12B} and H_{18A}), 1.47 (3H, s, C₁₄Me), 1.39 (1H, m, H₁₇), 1.30 (1H, m, H_{18B}), 1.20 (3H, d, $J = 6.9$ Hz, C₁₀Me), 1.08 (26H, Si^tPr₃, Me and 2 x H₁₁), 0.96 (3H, d, $J = 6.9$ Hz, Me), 0.93 (3H, d, $J = 7.0$ Hz, Me), 0.74 (3H, d, $J = 6.3$ Hz, C₁₇Me). $^{13}\text{C NMR } \delta$ (100 MHz, CDCl_3) 167.2, 160.0, 144.5, 139.3, 134.4, 132.9, 131.7, 131.1, 130.9, 128.7, 127.5, 120.6, 113.7, 96.2, 88.2, 81.4, 79.9, 77.3, 72.5, 65.7, 55.8, 55.7, 55.3, 41.8, 41.3, 36.8, 36.2, 36.1, 35.9, 35.5, 30.4, 29.9, 29.7, 28.9, 19.7, 18.0, 17.9, 15.8, 15.5, 14.0, 11.8, 10.9, 10.0.
7. We initially examined the HWE coupling of **5** with **6** to give enone **i**. A Mukaiyama aldol coupling of the silyl enol ether from **i** with aldehyde **ii** (derived from the corresponding alcohol, see preceding paper) proceeded under Felkin-Anh control to give adduct **iii**, which was then transformed by substrate-controlled reduction (ref. 19) into the methyl ether **iv**. However, subsequent deoxygenation of the C₁₁ hydroxyl proved problematic.



Conditions: (a) $\text{Ba}(\text{OH})_2$, $\text{THF}/\text{H}_2\text{O}$ (40:1), 20 °C, 2 h; (b) TESCl , LiHMDS , THF , -78 °C, 30 min; **ii**, $\text{BF}_3 \cdot \text{OEt}_2$, -60 °C, 48 h; (c) SmI_2 , EtCHO , THF , 0 °C, 3 h; (d) MeOTf , 2,6-di-*tert*-butylpyridine, CH_2Cl_2 , 20 °C, 2 h; (e) K_2CO_3 , MeOH , 20 °C.

8. (a) Grieco, P. A.; Pogonowski, C. S. *J. Am. Chem. Soc.* **1973**, *95*, 3071. (b) Grieco, P. A.; Finkelhor, R. S. *J. Org. Chem.* **1973**, *38*, 2909. (c) Grieco, P. A.; Pogonowski, C. S. *Synthesis* **1973**, 425.
9. Paterson, I.; Yeung, K.-S.; Smail, J. B. *Synlett* **1993**, 774.
10. Corey, E. J.; Bakshi, R. K.; Shibata, S.; Chen, C.-P.; Singh, V. K. *J. Am. Chem. Soc.* **1987**, *109*, 7925.
11. The scope of this novel oxidation/deprotection reaction is being investigated.
12. (a) Lindgren, B. O.; Nilsson, T. *Acta Chem. Scand.* **1973**, *27*, 888. (b) Bal, B. S.; Childers, W. E., Jr.; Pinnick, H. W. *Tetrahedron* **1981**, *37*, 2091.
13. Intermolecular acylation of a truncated C₂₁-C₂₇ diol with Bz_2O favoured reaction at the desired C₂₃ hydroxyl (4:1).
14. Hikota, M.; Sakurai, Y.; Horita, K.; Yonemitsu, O. *Tetrahedron Lett.* **1990**, *31*, 6367.
15. Inanaga, J.; Hirata, K.; Saeki, H.; Katsuki, T.; Yamaguchi, M. *Bull. Chem. Soc. Jpn.* **1979**, *52*, 1989.
16. Paterson, I.; Yeung, K.-S.; Ward, R. A.; Smith, J. D.; Cumming, J. G.; Lamboley, S. *Tetrahedron* **1995**, *51*, 9467.
17. (a) Seebach, D.; Hungerbühler, E.; Naef, R.; Schnurrenberger, P.; Weidmann, B.; Züger, M. *Synthesis*, **1982**, 138. (b) Paterson, I.; Watson, C.; Yeung, K.-S.; Wallace, P. A.; Ward, R. A. *J. Org. Chem.* **1997**, *62*, 452.
18. The 24 and 26-membered macrocycles were distinguished using 1D- and 2D-NMR techniques. In particular, compound **2** showed a diagnostic coupling between H₂₂ and H₂₃.
19. Evans, D. A.; Hoveyda, A. H. *J. Am. Chem. Soc.* **1990**, *112*, 6447.